Boston Scientific Letters of Credit Outstanding, Amount increased by 1.4% to $223.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.2%, from $216.00M to $223.00M. Over 4 years (FY 2020 to FY 2024), Letters of Credit Outstanding, Amount shows an upward trend with a 13.5% CAGR.
other_letters_of_credit_outstanding_amount| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $135.00M | $135.00M | $134.00M | $132.00M | $128.00M | $120.00M | $135.00M | $143.00M | $148.00M | $151.00M | $174.00M | $174.00M | $189.00M | $216.00M | $206.00M | $218.00M | $220.00M | $223.00M |
| QoQ Change | — | +0.0% | -0.7% | -1.5% | -3.0% | -6.3% | +12.5% | +5.9% | +3.5% | +2.0% | +15.2% | +0.0% | +8.6% | +14.3% | -4.6% | +5.8% | +0.9% | +1.4% |
| YoY Change | — | — | — | — | -5.2% | -11.1% | +0.7% | +8.3% | +15.6% | +25.8% | +28.9% | +21.7% | +27.7% | +43.0% | +18.4% | +25.3% | +16.4% | +3.2% |